AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
73.10
+1.60 (+2.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close71.50
Open72.00
Bid64.00 x 1400
Ask74.85 x 1400
Day's Range71.95 - 74.55
52 Week Range47.05 - 74.55
Volume542,248
Avg. Volume382,841
Market Cap2.887B
Beta1.01
PE Ratio (TTM)N/A
EPS (TTM)-4.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est82.30
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. The net inflows of $1.94 billion over the last one-month into ETFs that hold AERI are not among the highest of the last year and have been slowing.

  • TheStreet.com18 days ago

    Aerie Pharmaceuticals Has Broken Out on the Upside

    In this daily bar chart of AERI, below, we can see a decline from December to early May. Despite this decline from $64 to $48 we can see that the daily On-Balance-Volume (OBV) held steady suggesting that traders and investors in AERI did not become aggressive sellers. At the end of May the direction of the OBV line turns up sharply to make a new high.

  • Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) Shift From Loss To Profit
    Simply Wall St.19 days ago

    Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) Shift From Loss To Profit

    Aerie Pharmaceuticals Inc’s (NASDAQ:AERI): Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.Read More...

  • ACCESSWIRE20 days ago

    Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Aerie Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 25, 2018 / U.S. markets were mixed Friday, with the Dow snapping an eight day losing streak as energy shares rallied. However, major indexes experienced weekly losses on ...

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit22 days ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Aerie Pharmaceuticals Inc NASDAQ NMS:AERI

  • Business Wire27 days ago

    Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of William Coppola as Intellectual Property Counsel, reporting to John LaRocca, Aerie’s General Counsel. Mr. Coppola will oversee intellectual property matters both domestically and internationally on behalf of the Company. Mr. Coppola previously held related positions at Sanofi.

  • Business Wirelast month

    Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the JMP Securities 2018 Life Science Conference on Thursday, June 21, 2018 at 2:00pm Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update. The fireside chat will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of AERI earnings conference call or presentation 8-May-18 9:00pm GMT

    Q1 2018 Aerie Pharmaceuticals Inc Earnings Call

  • Aerie Pharmaceuticals (AERI) Up 16.7% Since Earnings Report: Can It Continue?
    Zackslast month

    Aerie Pharmaceuticals (AERI) Up 16.7% Since Earnings Report: Can It Continue?

    AERI reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.

  • Who Just Ramped Up Their Shares In QEP Resources And More?
    Simply Wall St.last month

    Who Just Ramped Up Their Shares In QEP Resources And More?

    Using insider buying as an indicator of when to buy makes sense. Company executives and directors have the most recent and in-depth information on the prospect of their firm. TheyRead More...

  • Business Wirelast month

    Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the NASDAQ 38th Investor Conference on Tuesday, June 12, 2018 at 9:00am British Summer Time in London, UK. Mr. Rubino will provide an Aerie overview and business update. The presentation will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/.

  • Business Wirelast month

    Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30pm Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update. The presentation will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/.

  • Business Wire2 months ago

    Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Lily Nguyen as Director, Project Management, reporting to Kenneth Ruettimann, Ph.D., Aerie’s Vice President of Manufacturing. Ms. Nguyen will direct strategic plan development and oversee ongoing project progress in the manufacturing department. Ms. Nguyen previously held related positions at Roivant Sciences and Cempra, Inc.

  • Are Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) Interest Costs Too High?

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Aerie Pharmaceuticals Inc (NASDAQ:AERI), with a market capitalization of US$2.02B, rarely draw their attention from the investingRead More...

  • ACCESSWIRE2 months ago

    Wired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache

    LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On May 15, 2018, the Company announced that a Phase-3 study evaluating galcanezumab in patients with episodic cluster headache met its primary endpoint, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. There were also a statistically significantly greater percentage of patients treated with galcanezumab who achieved at least a 50% reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint.

  • Aerie submits second drug for FDA approval
    American City Business Journals2 months ago

    Aerie submits second drug for FDA approval

    Aerie Pharmaceuticals has submitted its second glaucoma drug, Roclatan, to the U.S. Food and Drug Administration for potential approval.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! MEDIGUS Ltd/S ADR (NASDAQ: MDGS ) stock gained more ...

  • Business Wire2 months ago

    Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%. RoclatanTM is a once-daily eye drop designed to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

  • Aerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa
    Zacks2 months ago

    Aerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa

    Aerie (AERI) reported a narrower-than-expected loss in the first quarter. The launch of the lead drug Rhopressa is underway.

  • With $334M in cash, Aerie preps to break even
    American City Business Journals2 months ago

    With $334M in cash, Aerie preps to break even

    With $334 million in cash, equivalents and investments as of March 31 and its first drug launched, Durham’s Aerie Pharmaceuticals is prepped to break even.

  • Associated Press2 months ago

    Aerie: 1Q Earnings Snapshot

    On a per-share basis, the North Carolina, North Carolina-based company said it had a loss of $1.05. Losses, adjusted for stock option expense, were 83 cents per share. The results topped Wall Street expectations. ...

  • Business Wire2 months ago

    Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2018, along with a general business update.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie Pharmaceuticals, Forrester Research, and Diamond Hill Investment Group — Discovering Underlying Factors of Influence

    NEW YORK, May 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Roper ...

  • What's in the Cards for Aerie (AERI) This Earnings Season?
    Zacks2 months ago

    What's in the Cards for Aerie (AERI) This Earnings Season?

    Investors are expected to focus on Rhopressa's launch and other pipeline updates when it reports results for the first-quarter (scheduled on May 8).

  • Durham pharma launches first drug with another on horizon
    American City Business Journals2 months ago

    Durham pharma launches first drug with another on horizon

    Aerie Pharmaceuticals has launched its first drug and has another one awaiting approval from the U.S. Food and Drug Administration.